Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Payables (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Payables for 7 consecutive years, with $12.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables rose 46.59% year-over-year to $12.4 million, compared with a TTM value of $12.4 million through Dec 2025, up 46.59%, and an annual FY2025 reading of $12.4 million, up 46.59% over the prior year.
  • Payables was $12.4 million for Q4 2025 at Avidity Biosciences, up from $9.6 million in the prior quarter.
  • Across five years, Payables topped out at $54.2 million in Q1 2025 and bottomed at $3.9 million in Q2 2025.
  • Average Payables over 5 years is $24.6 million, with a median of $23.5 million recorded in 2022.
  • The sharpest move saw Payables surged 140.71% in 2022, then crashed 90.44% in 2025.
  • Year by year, Payables stood at $14.1 million in 2021, then skyrocketed by 131.25% to $32.6 million in 2022, then increased by 5.43% to $34.3 million in 2023, then tumbled by 75.36% to $8.5 million in 2024, then skyrocketed by 46.59% to $12.4 million in 2025.
  • Business Quant data shows Payables for RNA at $12.4 million in Q4 2025, $9.6 million in Q3 2025, and $3.9 million in Q2 2025.